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Objectives. We investigated the role of endogenous endothelin-1 
in the development of cardiac hypertrophy in vivo under pressure 
overload conditions. 
Background. Endothelin-1, a potent vasoconstrictor peptide, 
has recently been shown to act as a growth factor of myocardial 
cells in culture. 
Methods. We examined the effect of an endothelin-A receptor 
antagonist (FR139317) on the development of right ventricular 
hypertrophy in rats with monocrotaline-induced pulmonary hy- 
pertension. Three groups of rats were studied: those given mono- 
crotaline alone or monocrotaline plus FR139317 and those given 
vehicle alone (control group). 
Results. The ratio of right ventricular systolic pressure to aortic 
systolic pressure was similarly elevated in rats treated with 
monocrotaline and monocrotaline plus FR139317. The right 
ventricular/left ventricnlar weight ratio was increased in 
monocrotaline-treated rats but lower in rats treated with mono- 
crotaline plus FR139317 than in those treated with monocrotaline 
alone (p < 0.01). As a biochemical marker of hypertrophy, the 
isoform ratio of beta-myosin heavy chain protein was determined 
for the right ventricular tissue samples. This ratio was increased 
in all monocrotaline-treated rats but was lower (p < 0.01) in rats 
given monocrotaline plus FR139317 than in those given monocro- 
taline alone. The isoform ratio of beta-myosin heavy chain mes- 
senger ribonucleic acid qnantitated by S1 nuclease mapping also 
was lower (p < 0.025) in rats receiving monoerotaline plus 
FR139317 than in those receiving monocrotaline alone. 
Conclusions. These data suggest hat blocking the action of 
endothelin.1 with a receptor antagonist ameliorates cardiac hy- 
pertrophy in this model system, and that this action is not 
mediated by ameliorating hemodynamic changes. 
(J Am CoU Cardiol 1996;27:1286-91) 
Endothelin-1 is a potent vasoconstrictor peptide originally 
isolated from porcine aortic endothelial cells (1). It has also 
been found to act as a growth factor and mitogen of vascular 
smooth muscle cells. Because of its potential role in vascular 
diseases such as hypertension a d atherosclerosis, it  biology 
and that of its high affinity receptors endothelin-A (ETA) and 
endothelin-B (ETB) have been intensively studied (2,3). Re- 
cently, the physiologic actions of endothelin-1 in the myocar- 
dium have been investigated. Endothelin-1 has a positive 
inotropic effect on myocardial cells (4). It has also been shown 
to act as a growth factor, inducing deoxyribonucleic acid synthesis, 
promoting expression of protooncogenes and muscle-specific 
genes in culture (5-9). 
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Cardiac hypertrophy is a major adaptational mechanism to
stresses such as pressure overload and neurohormonal stimu- 
lation. Many characteristic molecular changes have been de- 
scribed in association with the development of ventricular 
myocardial hypertrophy. Expression of immediate and early 
response genes is induced and there is a reappearance of
"fetal" proteins such as beta-myosin heavy chain, alpha- 
skeletal actin and atrial natriuretic peptide (10). Because 
isoform distribution of myosin heavy chain is known to regu- 
late contraction velocity and energy efficiency, much work has 
focused on these molecules (11). It is well known that alpha- 
myosin heavy chain isoform is the dominant form of myosin in 
the adult rat ventricular myocardium (11), and many labora- 
tories including this one have demonstrated the switching from 
alpha- to beta-myosin heavy chain isoforms that occurs during 
the development ofcardiac hypertrophy (12-14). 
Because of the ability of endothelin-1 to regulate funda- 
mental molecular processes in myocardial cells, we hypothe- 
sized that this peptide may be involved in the development of 
ventricular hypertrophy. Although several experimental in vivo 
models have been used to study cardiac hypertrophy induced 
by pressure overload, we chose the highly reproducible model 
of monocrotaline-induced pulmonary hypertension for these 
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studies. Monocrotaline, a pyrrolizidine alkaloid derived from 
Crotalaria spectabilis, is known to cause pulmonary hyper- 
tension and fight ventricular hypertrophy b  producing pulmo- 
nary vasculitis (15-18). To investigate a potential role of the 
endothelin-1 peptide in the development of right ventricular 
hypertrophy, we employed a potent and specific endothelin-A 
(ETA) receptor antagonist, FR139317. The pharmacologic 
profile of this substance on the effect of endothelin-1 has been 
well characterized (19). 
The use of this ETA antagonist enabled us to investigate he 
role of endogenous endothelin-1 in the development ofventric- 
ular hypertrophy in vivo under pressure overload conditions. 
FR139317 was coadministered to monocrotaline-treated rats at a 
dose that did not eliminate monocrotaline-induced pulmonary 
hypertension. Although elevated pulmonary pressures developed 
in rats that received FR139317, this group had a significantly 
smaller increase in fight ventricle/left ventricle weight ratio. 
Myosin heavy chain isozymic expression was evaluated as a 
biochemical marker of hypertrophy, and the endothelin-1 antag- 
onist was shown to significantly decrease the appearance of 
beta-myosin heavy chain protein and messenger ribonudeic acid 
(mRNA). These data thus demonstrate that the ETA receptor 
antagonist FR139317 eliminates monocrotaline-induced right 
ventricular hypertrophy and myosin heavy chain isoform transi- 
tion, and they suggest arole for endogenous endothelin-1 in the 
pathophysiology of this process. 
Methods  
Animals and physiologic studies. Twenty-nine male Wistar 
rats (age 4 weeks) were divided into three groups: 1) the 
monocrotaline group (9 rats given a single subcutaneous dose 
[60 mg/kg body weight] of monocrotaline) (Sigma Co. Ltd.) 
followed by daily subcutaneous administration f saline solu- 
tion for 21 days; 2) the monocrotaline plus FR139317 group 
(10 rats given a single subcutaneous dose of monocrotaline 
followed by 10 mg/kg per day, subcutaneously, of the ETA 
receptor antagonist FR139317) [Fujisawa Pharmaceutical Co. 
Ltd., Osaka, Japan] [19] for 21 days; and 3) the Control group 
(10 rats given a subcutaneous dose of monocrotaline v hicle 
followed by daily subcutaneous administration f saline solu- 
tion for 21 days). 
After 21 days, under pentobarbital sodium anesthesia 
(50 mg/kg), right ventricular systolic pressure was measured 
with a water-sealed flexible catheter through the right jugular 
vein and systolic arterial pressure measured through a 27- 
gauge needle in the carotid artery. For both measurements a 
physiologic transducer (Nihon Koden Co. Ltd., Tokyo, Japan) 
was employed. Blood samples were then taken and the rats 
killed. The heart was rapidly excised, the atria and great vessels 
were removed and the right ventricular f ee wall was sepa- 
rated. The right ventricle and the left ventricle with the septum 
were rinsed with ice-cold saline solution, blotted ry, weighed, 
frozen in liquid nitrogen and stored at -80°C. 
Measurement of plasma endothelin-1 concentration. Each 
blood sample was placed in a chilled tube containing aprotinin 
(300 kallikrein-inhibiting U/ml) and ethylenediaminetetraace- 
tic acid (2 mg/ml), and plasma was separated immediately by 
centrifuging at 2,000 g for 15 rain at 4°C. The plasma was 
stored at -80°C. Determination of plasma endothelin-1 con- 
centration was carried out by using sandwich-enzyme immu- 
noassay for endothelin-1 as previously described (20). In brief, 
immunoreactive endothelin-1 was extracted with a Sep-pak 
C-18 cartridge after acidification of plasma with acetic acid, 
reconstituted with assay buffer and subjected to sandwich- 
enzyme immunoassay using immobilized mouse monoclonal 
antibody. The detection limit of this enzyme immunoassay was 
0.4 pg/ml. 
Myosin heavy chain isoform analysis. Extraction of crude 
myosin from the myocardium was performed at 4°C with 
Hasselbach-Schneider solution as previously described (13), 
and isoforms were separated by 3.7% polyacrylamide gel 
electrophoresis in the presence of 20-mmol/liter sodium pyro- 
phosphate, according to the modified method of Hob et al. 
(21). The density of each band (V1, V2 and V3) was measured 
with a laser densitometer (Ultroscan XL, Pharmacia), and the 
relative amount of alpha- and beta-myosin heavy chain was 
calculated. The half-value of V2 density was added to those of 
V1 and V3. 
Myosin heavy chain isoform mRNA analysis (S1 mapping 
analysis). Total ribonucleic acid (RNA) from the right ventri- 
cle was extracted by the acid guanidinium thiocyanate-phenol- 
chloroform ethod (22). $1 mapping analysis of myosin heavy 
chain mRNA was performed as previously described (13). The 
complement deoxyribonucleic acid (eDNA) probe used in this 
study was the 3' Pst I fragment of pCMHC mini5 (beta-myosin 
heavy chain eDNA clone) provided by Dr. B. Nadal-Ginard 
(Harvard Medical School, Boston, MA) (23). The probe was 
hybridized in deoxyribonucleic a id excess to -30 mg total 
RNA in 80% formamide for 18 h at 42°C. $1 nuclease 
digestion was done for 1 h, and the digestion products were 
separated on a 6% acrylamide and 8.3 mol/liter urea- 
sequencing el. The proportion of alpha- and beta-myosin 
heavy chain mRNA was quantitated by densitometry (UI- 
troscan XL, Pharmacia) of the autoradiograph. 
Statistical analysis. The results are expressed as mean 
value _+ SD. Statistical comparisons among more than three 
groups were carried out by using analysis of variance and the 
Newman-Keul test for multiple sample comparisons. Compar- 
isons between two groups were performed by unpaired Student 
t test. The relative data (myosin heavy chain isozyme and 
mRNA) were evaluated after transformation to normal distri- 
bution of values by using the arcsine transformation (24). In 
either test, a p value < 0.05 was considered statistically 
significant. 
Results  
Hemodynamic studies and plasma endothelin-1 concentra. 
tion. Right ventricular systolic pressure and the right ventric- 
ular systolic pressure/aortic pressure ratio are shown in Figure 
1. Right ventricular systolic pressure of monocrotaline-treated 
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Figure 1. Bar graphs howing the right ventricular systolic pressure 
(RVSP) (left panel) and the ratio of right ventricular systolic pressure/ 
aortic systolic pressure (RVSP/AoSP) (right panel) in the control 
group (n = 10) and rats treated with monocrotaline (MCT) (n = 9) or 
with monocrotaline plus FR139317 (MCT + FR) (n = 10). Values for 
these indexes did not differ significantly in rats treated with monocro- 
taline or monocrotaline plus FR139317, but were significantly higher in 
these groups than values in control rats (p < 0.01). Data are expressed 
as mean value _+ SD. 
rats was significantly higher than that of control rats (65.0 + 
16.0 vs. 32.1 _+ 7.1 mm Hg, p < 0.01). To eliminate the effect 
of systemic arterial pressure at the time of pressure measure- 
ment, we calculated the right ventricular systolic pressure/ 
aortic pressure ratio. Similarly, monocrotaline-treated rats 
showed a higher ight ventricular systolic pressure/aortic pres- 
sure ratio than that of control rats (0.60 _+ 0.06 vs. 0.24 + 0.05, 
p < 0.01). 
The right ventricular systolic pressure and right ventricular 
systolic pressure/aortic pressure ratio of rats treated with 
monocrotaline plus FR139317 were also elevated compared 
with values in the control group (right ventricular systolic 
pressure 62.7 + 7.9 mm Hg, right ventricular systolic pressure/ 
aortic pressure ratio 0.60 + 0.10, p < 0.01), and there was no 
significant difference in these measurements between rats 
treated with monocrotaline or rnonocrotaline plus FR139317 
(Fig. 1). These data indicate that at the dose of 10 mg/kg per 
day used in this study, FR139317 had no significant effect on 
the elevated right heart pressures induced by monocrotaline. 
Pressure overload was thus equivalent in the groups treated 
with monocrotaline and monocrotaline plus FR139317. 
Plasma endothelin-I levels. Plasma endothelin-1 concen- 
tration was significantly higher in the rats treated with mono- 
crotaline and monocrotaline plus FR139317 (3.28 + 1.82 and 
2.58 +_ 0.74 pg/ml, respectively) than in control rats (1.26 _+ 
0.43 pg/ml, p < 0.01), but there was no difference between the 
monocrotaline and monocrotaline plus FR139317 groups. 
Left and right ventrieular weight. Body weight of rats in 
the control group and of those treated with monocrotaline 
or monocrotaline plus FR139317 was 187 +_ 42, 153 _+ 21 and 
158 +_ 19 g, respectively (p = NS). There was no significant 
difference in left ventricular weight between these three groups 
(0.46 _+ 0.09, 0.41 _+ 0.04, 0.46 +_ 0.06 g, respectively). Right 
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Figure 2. Bar graph showing the weight ratio of the right ventricle 
(RV) to the left ventricle (LV) with the septurn. Although the ratio in 
rats receiving monocrotaline (n = 9) and monocrotaline plus 
FR139317 (n = 10) was significantly higher (p < 0.01) than that in 
control rats (n = 10), it was significantly lower (p < 0.01) in the group 
receiving monoerotaline plus FR139317 than in the group receiving 
monocrotaline alone. Data are expressed as mean value _ SD. 
Abbreviations a in Figure 1. 
monocrotaline (0.28 +__ 0.04 g) or monocrotaline plus 
FR139317 (0.24 _+ 0.05 g) than in the control group (0.13 +-- 
0.03, p < 0.01). The right ventricle/left ventricle weight ratio 
was significantly higher in monocrotaline-treated rats than in 
control rats (0.67 +- 0.05 vs. 0.28 _ 0.05, p < 0.01) (Fig. 2). 
Although this ratio was also increased in rats treated with 
monocrotaline plus FR139317 (0.54 _+ 0.10, p < 0.01, vs. 
control), it was significantly ower (p < 0.01) in this group than 
in the group treated with monocrotaline alone. This latter 
difference was surprising in view of the same degree of right 
ventricular pressure overload in these two groups. 
Transition of myosin heavy chain isoform. To assess 
whether the ETA receptor antagonist was able to modify the 
hypertrophy-associated transition from the alpha- to the beta- 
myosin heavy chain isoform, we performed pyrophosphate g l
electrophoresis to analyze the cardiac myosin heavy chain 
isoform expression. Figure 3A shows the representative pyro- 
phosphate gel electrophoresis of myosin extracted from the 
ventricles of rats in the control and treated groups. Three 
bands, V1 (as), V2 (a/3) and V3 (/3/3), were visible in 
monocrotaline-treated rats,whereas only one band (V1) was 
visible in control rats. Although three bands were also visible in 
the tissue samples from rats treated with monocrotaline plus 
FR139317, the intensity of the V3 band was weaker than that 
seen with those treated with monocrotaline alone. 
The proportion of beta-myosin heavy chain in right ventric- 
ular myocardium was greater in monocrotaline-treated than in 
control rats (lane 2, monocrotaline group 0.21 +- 0.01 vs. lane 
1, control group 0.03 _+ 0.03, p < 0.01) (Fig. 3B). However, rats 
treated with monocrotaline plus FR139317 showed signifi- 
cantly lower ratios of beta-myosin heavy chain (0.08 _+ 0.04) 
than did rats treated with monocrotaline alone (lane 2 vs. lane 
3, p < 0.01). The proportion of beta-myosin heavy chain in left 
ventricular tissue samples was not significantly different among 
the three groups (control 0.02 -+ 0.02, monocrotaline 0.07 _ 
0.06, monocrotaline plus FR139317 0.05 _ 0.03). Therefore, 
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Figure 3. Myosin heavy chain (MHC) isoform distribution of right 
ventricular myocardiurn i  the three groups of rats. A, Representative 
pattern of pyrophosphate g l electrophoresis and isoforrnic profile of 
myosin heavy chain isoform. B, Bar graph showing the relative ratio of 
beta-rnyosin heavy chain isoform in control rats (n = 10) and rats 
receiving rnonocrotaline (n= 9) or monocrotaline plus FR139317 (n = 
10). Although the proportion of beta-rnyosin heavy chain in the two 
groups receiving monocrotaline was significantly higher (p < 0.0i) 
than that in the control group, it was also lower (p < 0.01) in rats 
receiving rnonocrotaline plus FR139317 than in rats receiving rnono- 
crotaline alone. Data are expressed as mean value _+ SD. Abbrevia- 
tions as in Figure 1. 
transition of alpha- to beta-myosin heavy chain isoforms in 
the right ventricle was induced during the development of
monocrotaline-induced hypertrophy, and the ETA receptor 
antagonist partially inhibited this transition. 
Transition of myosin heavy chain mRNA. We next exam- 
ined whether these changes in the relative ratio of alpha- and 
beta-myosin heavy chain proteins reflected corresponding 
changes at the mRNA level. The relative levels of mRNAs 
coding for the alpha- and beta-myosin heavy chain were 
quantitated by S1 nuclease mapping. Figure 4A shows a 
representative S1 mapping analysis of the alpha- and beta- 
myosin heavy chain mRNAs. Figure 4B shows quantitative 
composite data reflecting the proportion of beta-myosin heavy 
chain to total myosin heavy chain mRNA for the three 
experimental groups. In the control rats the alpha-myosin 
heavy chain mRNA was predominant, and in monocrotaline- 
treated rats the beta-myosin heavy chain mRNA was predom- 
inant. This finding was reflected in a significant difference in 
the proportion of beta-myosin heavy chain between the two 
groups (lane 2, monocrotaline group 0.63 _+ 0.27 vs. lane 1, 
A 
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Figure 4. Myosin heavy chain (MHC) isoform messenger ribonucleic 
acid (mRNA) distribution of right ventricular myocardium inthe three 
groups of rats. A, Representative pattern of S1 mapping analysis of 
myosin heavy chain isoforrn mRNA. B, Bar graph showing the relative 
ratio of beta-rnyosin heavy chain isoforrn mRNA in the control rats 
(n = 10) and rats receiving monocrotaline (n = 9) and rnonocrotaline 
plus FR139317 (n = 10). Although the proportion of beta-myosin 
heavy chain rnRNA was significantly higher (p < 0.01) in rats receiving 
monocrotaline ormonocrotaline plus FR139317 than in control rats, it 
was significantly lower (p < 0.025) in rats receiving monocrotaline plus 
FR139317 than in rats receiving rnonocrotaline alone. Data are 
expressed as mean value _+ SD. Abbreviations as in Figure l. 
control group 0.03 + 0.02, p < 0.01). Although the alpha- 
myosin heavy chain mRNA was detected in samples from rats 
treated with monocrotaline plus FR139317, the proportion of 
beta-myosin heavy chain was significantly lower than that of 
rats treated with monocrotaline alone (lane 2, monocrotaline 
group 0.63 -+ 0.27 vs. lane 3, monocrotaline plus FR139317 
group 0.33 -+ 0.23, p < 0.025). 
Discuss ion  
Right ventricular hypertrophy induced by pressure over- 
load and the role of endothelin-l. In this study, we investigated 
the role of endogenous endothelin-1 on the development of 
anatomic and molecular characteristics of cardiac hypertrophy. 
This was studied by administration of a receptor antagonist 
specific for the ETA receptor during the development of right 
ventricular pressure overload resulting from monocrotaline- 
induced pulmonary vascular disease. This model system was 
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chosen because of its reproducibility and because the left 
ventricle remains unaffected and left ventricular pressures and 
anatomy can serve as internal controls. As expected, monocro- 
taline alone produced right ventricular hypertrophy associated 
with elevated pulmonary artery pressures. Although adminis- 
tration of the receptor antagonist did not significantly blunt the 
pressure response, it did significantly block the hypertrophic 
response to the pressure increase. Miyauchi et al. (25) showed 
that another ETA receptor antagonist, BQ123, prevented 
development of right ventricular hypertrophy while also pre- 
venting pulmonary hypertension. However, they used a higher 
daily dose of ETA receptor antagonist han the dose of 
FR139317 we used. Recently, Ito et al. (26) reported that 
BQ123 blocked left ventricular hypertrophy in an aortic band- 
ing model. Taken together, these data obtained with very 
different models of ventricular hypertrophy and employing 
different ETA antagonists provide a compelling argument that 
endothelin-1 is involved in the pathophysiology of the hyper- 
trophic response. 
To determine whether the ETA receptor antagonist could 
alter the molecular program associated with the myocardial 
response to increased pressure, we evaluated the myosin heavy 
chain isoform pattern in the experimental nd control rats. 
Monocrotaline-treated rats developed the characteristic alpha- 
to beta-myosin heavy chain isoform transition, as documented 
by both protein and mRNA studies. FR139317 was shown to 
inhibit the myosin heavy chain isoform switch. These data thus 
suggest that the ETA receptor antagonist inhibits the molec- 
ular program that directs or is associated with the anatomic 
changes of hypertrophy. 
Endothelin-1 signal transduction system in myocardial 
cells. In vascular smooth muscle cells, endothelin-1 acts through 
its specific ETA receptor, and signals from this receptor stimulate 
phosphatidyl inositol production, activate protein kinase C and 
lead to vascular smooth muscle cell contraction and growth (27). 
Recently, exogenous endothelin-1 was shown (7,9) to induce 
phosphatidyl inositol response, protein kinase C activation and 
cardiac gene expression in myocardial ceils in culture. Protein 
kinase C activation has been linked to cardiac hypertrophy. It has 
been described that angiotensin II and mechanical stretch induce 
cardiac gene expression and myocardial cell growth through the 
protein kinase C pathway (28-32). Also, up-regulation of beta- 
myosin heavy chain gene expression by alpha-adrenergic receptor 
stimulation has been shown (33-35) to involve protein kinase C. 
If endothelin-1 isdirectly involved in the pathogenesis of hyper- 
trophy, as implied from our receptor antagonist data, it would 
seem most likely to result from protein kinase C activation. This 
possible role of protein kinase C in the endothelin-l-induced 
cellular changes associated with elevated ventricular pressures 
will be directly addressed experimentally in future studies. 
Plasma endothelin-1 levels were elevated in monocrotaline- 
treated rats, but these levels did not differ between rats treated 
with monocrotaline and monocrotaline plus FR139317. The 
elevated endothelin-1 levels in the rats in which hypertrophy 
developed is consistent with a role for endothelin-1 in this 
process. These findings may reflect he increased local expres- 
sion of endothelin-1, as prepro endothelin-1 mRNA in the 
heart has been shown (25) to be increased in monocrotaline- 
treated rats. These data are consistent with a functional role 
for endothelin-1 as a paracrine or autocrine factor in the 
development of cardiac hypertrophy in vivo. 
Clinical implications, Findings reported here and in the 
recent work by Ito et al. (26) have important implications for 
the treatment of clinical cardiac hypertrophy. In recent years, 
the role of the local cardiac renin-angiotensin system in the 
development ofcardiac hypertrophy has been intensively stud- 
ied (36). Clinical trials (37,38) have shown the beneficial effects 
of angiotensin-converting e zyme inhibitors, which are able to 
inhibit cardiac hypertrophy and improve the prognosis of 
patients with congestive heart failure. Very recently, clinical 
trials of angiotensin II receptor antagonists in patients with 
heart failure (39) have also been reported. In a similar fashion, 
blocking the action of endogenous endothelin-1 at the myo- 
cardial cells with an ETA receptor antagonist may provide an 
additional treatment for cardiac hypertrophy. 
Summary. In summary, ETA receptor antagonist prevents 
the transition of myosin heavy chain isoform and regresses the 
right ventricular hypertrophy in rats with monocrotaline- 
induced pulmonary hypertension without changing the pres- 
sure loading condition. These data demonstrate hat endoge- 
nous endothelin-1 contributes to the progression of cardiac 
hypertrophy independent of the pressure overload in vivo. 
We thank Makiko Hatsumi, BS, Taeko Hokari, BS, and Eriko Hiratsuka, BS, for 
technical assistance in these experiments. 
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